新单抗ZCH-7-2D3与白血病细胞的反应性及其临床意义

目的：观察新抗人白细胞分化抗原ZCH-7-2D3单克隆抗体（单抗）与白血病细胞的反应性及其在白血病免疫学诊断分型中的意义。方法：采用CD45设门和多色流式细胞术，对经30余种标准单抗业已定型的100例白血病患者新鲜的骨髓细胞或外周血标本进行流式细胞术分析。结杲：2D3抗原在急性淋巴细胞性白血病（ALL）病例中的阳性率（10／31）明显低于急性髓细胞性白血病（AML）（39／55，P〈0．01）；2D3在3例B系／髓系混合型白血病病例中均有表达，而在6例慢性粒细胞性白血病（CML）中不表达，在慢性淋巴细胞性白血病（CLL）中阳性率（3／5）与B系ALL病例中的阳性率（9／28）差异无显著意义（P=0．2389）。2D3在ALL各免疫亚型中的表达差异无显著意义（P=0．5632）；在AML各亚型中除2例AML—M6患者不表达外，其余AML亚型间无统计学意义（P〉0．05）。结论：单抗2D3主要与AML细胞反应，但在识别白血病细胞分化阶段上未发现特殊性。

Reactivity of a novel monoclonal antibody ZCH-7-2D3 on leukemia cells and its clinical significance

Objective: To analyze the reactive pattern and its clinical significance of ZCH-7-2D3 monoclonal antibody on leukemia cells.Methods:Bone marrow samples from 100 leukemia patients(male 59:female 41,34 cases of children and 66 adults,aged 11 months-77 year) were collected.A CD45 gating strategy and multi-parameter flow cytometry were used to analyze the leukemia cells.Results: The positive rate(10/31) of 2D3 antibody on acute lymphocytic leukemia(ALL) patients was significantly lower than that(39/55) of acute myelogeneous leukemia(AML)(P<0.01).2D3 was positive for all three cases of B/myeloid mixed lineage leukemia,but negative in 6 cases of chronic myelogeneous leukemia(CML),significantly lower than that in AML(39/55,P<0.01) patients.There was no difference between the positive rates of chronic lymphocytic leukemia(CLL,3/5) and B lineage ALL(9/28,P = 0.2389).The antibody was not found to recognize the differentiation stages of either ALL and AML subtypes.Conclusion:2D3 monoclonal antibody primarily recognizes AML cases.Further studies on cloning of gene encoding the antigen protein and its biological functions are warranted.